The US Food and Drug Administration (FDA) has approved an updated label for Vabysmo (faricimab-svoa) to allow treatment of macular edema following retinal vein occlusion (RVO) beyond 6 months, according to an announcement from Genentech.

RVO affects more than 1 million individuals in the United States and is commonly managed with repeated intravitreal anti-VEGF therapy. The updated labeling reflects the chronic nature of the disease and the need for ongoing treatment in many patients.

Faricimab is a bispecific antibody that targets both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), pathways implicated in vascular instability and leakage. Dual inhibition is intended to promote vascular stabilization and reduce inflammation.

Levi Garraway, MD, PhD, Genentech’s chief medical officer, said the update may reduce the need for treatment switches in patients who are responding to therapy. Veeral Sheth, MD, of University Retina and Macula Associates, noted that the revised dosing framework aligns with clinical practice and may support individualized treatment strategies.

Faricimab is also approved for neovascular age-related macular degeneration and diabetic macular edema. The updated indication expands its use in RVO. RP